Mayo Clinic Laboratory and Pathology Research Roundup: Feb. 11

By Kelley Luedke • February 11, 2019

Share this:

The Research Roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

EZH2 Cooperates with Gain-of-Function p53 Mutants to Promote Cancer Growth and Metastasis

In light of the increasing number of identified cancer-driven gain-of-function (GOF) mutants of p53, it is important to define a common mechanism to systematically target several mutants, rather than developing strategies tailored to inhibit each mutant individually. Here, using RNA immunoprecipitation-sequencing (RIP-seq), Mayo Clinic researchers identified the Polycomb-group histone methyltransferase EZH2 as a p53 mRNA-binding protein. EZH2 bound to an internal ribosome entry site (IRES) in the 5'UTR of p53 mRNA and enhanced p53 protein translation in a methyltransferase-independent manner. EZH2 augmented p53 GOF mutant-mediated cancer growth and metastasis by increasing protein levels of mutant p53. EZH2 overexpression was associated with worsened outcome selectively in patients with p53-mutated cancer. Depletion of EZH2 by antisense oligonucleotides inhibited p53 GOF mutant-mediated cancer growth. Our findings reveal a non-methyltransferase function of EZH2 that controls protein translation of p53 GOF mutants, inhibition of which causes synthetic lethality in cancer cells expressing p53 GOF mutants. The study was published in EMBO Journal.

Published to PubMed This Week

• • • • • Peripheral Neuropathy Associated with Silver Toxicity
          Neurology
          
        • Utility of the Serum Free Light Chain Assay in the Diagnosis of Light Chain Amyloidosis in Patients With Heart Failure
          Mayo Clinic Proceedings
          
        • Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015
          Mayo Clinic Proceedings
          
        • Association of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration
          JAMA Ophthalmology
          
        • Cancer Susceptibility Gene Mutations in Type I and II Endometrial Cancer
          Gynecologic Oncology
          
        • Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy
          Current Opinion in Neurology
          
        • Acute Leukemias Harboring KMT2A/MLLT10 Fusion: A 10-Year Experience from a Single Genomics Laboratory
          Genes Chromosomes Cancer
        • Genetics of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
          Aesthetic Surgery Journal
          
        • Impact of an Electronic Decision Support Rule on ESR/CRP Co-Ordering Rates in a Community Health System and Projected Impact in the Tertiary Care Setting and a Commercially Insured Population
          Clinical Biochemistry
          
        • Chondrosarcoma Arising Within Synovial Chondromatosis of the Lumbar Spine
          Skeletal Radiology
          
        • Variations in the Clinical Course of Patients with Herpes Simplex Virus Esophagitis Based on Immunocompetence and Presence of Underlying Esophageal Disease
          Digestive Diseases and Sciences
          
        • Update on Peripheral Nerve Sheath Tumors
          Surgical Pathology Clinics
        • Tropheryma whipplei Infection (Whipple Disease) in the USA
          Digestive Diseases and Sciences

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.